# Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST

> **NCT03858478** · PHASE4 · UNKNOWN · sponsor: **Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba** · enrollment: 110 (estimated)

## Conditions studied

- HIV Seropositivity

## Interventions

- **DRUG:** Biktarvy arm

## Key facts

- **NCT ID:** NCT03858478
- **Lead sponsor:** Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-18
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03858478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03858478, "Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03858478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*